Lu F M, Wang J, Chen X M, Zhang X X, Zhang W H, Xu X Y, Jia J D, Ren H
Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Department of Infectious Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zhonghua Gan Zang Bing Za Zhi. 2020 Aug 20;28(8):649-653. doi: 10.3760/cma.j.cn501113-20200722-00410.
Chronic hepatitis B (CHB) poses a serious threat to the health of the Chinese people. Viral markers are of great significance during antiviral therapy and research and development of innovative drugs. However, traditional serovirological markers such as HBV DNA and hepatitis B surface antigen (HBsAg) have certain limitations in assessing the efficacy of antiviral treatment and accurately reflecting the transcriptional activity of covalently closed circular DNA (cccDNA). In recent years, the role of new viral markers such as HBV RNA, hepatitis B core-related antigen (HBcrAg) and quantitative anti-hepatitis B core protein (qAnti-HBc) have attracted more and more attention because of accurately reflecting the transcription activity of cccDNA, determining the therapeutic effect and predicting the risk of recurrence after drug discontinuation. This article briefly introduces the application of new and old markers in various stages of antiviral therapy in CHB patients, and combines the application of new viral markers in the evaluation of drug efficacy, and expounds its possible role in the research and development of new antiviral therapy.
慢性乙型肝炎（CHB）对中国人民的健康构成严重威胁。病毒标志物在抗病毒治疗以及创新药物的研发过程中具有重要意义。然而，传统的血清学标志物如乙肝病毒脱氧核糖核酸（HBV DNA）和乙肝表面抗原（HBsAg）在评估抗病毒治疗疗效以及准确反映共价闭合环状DNA（cccDNA）的转录活性方面存在一定局限性。近年来，诸如乙肝病毒核糖核酸（HBV RNA）、乙肝核心相关抗原（HBcrAg）和定量抗乙肝核心蛋白（qAnti-HBc）等新型病毒标志物，因其能准确反映cccDNA的转录活性、确定治疗效果以及预测停药后复发风险，而受到越来越多的关注。本文简要介绍新旧标志物在CHB患者抗病毒治疗各阶段的应用情况，并结合新型病毒标志物在药物疗效评估中的应用，阐述其在新型抗病毒治疗研发中可能发挥的作用。
